Taysha Gene Therapies (TSHA) Other financing activities (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Other financing activities of $19000.0 for Q1 2026, down 74.67% on a YoY basis from $75000.0 in Q1 2025, and down 98.99% sequentially from $1.9 million in Q4 2025.
Taysha Gene Therapies (TSHA) Other financing activities (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 6 years of Other financing activities data on file, last reported at $19000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities fell 74.67% year-over-year to $19000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (up 1045.65% YoY), and the FY2025 full-year result was $1.6 million, up 1739.33% from the prior year.
- Other financing activities declined to $19000.0 in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $1.9 million in Q4 2025 to a low of -$1.3 million in Q4 2022.
- A 5-year average of $51400.0 and a median of $19000.0 in 2026 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities slumped 345.59% in 2023 and soared 530.1% in 2025, its largest moves.
- Tracing TSHA's Other financing activities over 5 years: stood at -$1.3 million in 2022, then jumped by 124.79% to $321000.0 in 2023, then dropped by 6.85% to $299000.0 in 2024, then soared by 530.1% to $1.9 million in 2025, then plunged by 98.99% to $19000.0 in 2026.
- Business Quant data shows TSHA's Other financing activities at $19000.0 in Q1 2026, $1.9 million in Q4 2025, and -$285000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,000.00 |
| Mar 31, 2026 | 19,000.00 |
| Dec 31, 2025 | 1.88 Mn |
| Dec 31, 2025 | 1.88 Mn |
| Sep 30, 2025 | -285,000.00 |
| Sep 30, 2025 | -285,000.00 |
| Jun 30, 2025 | -37,000.00 |
| Jun 30, 2025 | -37,000.00 |
| Mar 31, 2025 | 75,000.00 |
| Mar 31, 2025 | 75,000.00 |
| Dec 31, 2024 | 299,000.00 |
| Dec 31, 2024 | 299,000.00 |
| Sep 30, 2024 | -236,000.00 |
| Sep 30, 2024 | -236,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | 321,000.00 |
| Dec 31, 2023 | 321,000.00 |
| Sep 30, 2023 | -303,000.00 |
| Sep 30, 2023 | -303,000.00 |